The results of a Phase I/IIa dose-escalation study for ChemGenex’s investigational cancer drug Quinamed sheds light on how pharmacogenomics may be used to determine the right dose for patients.
The Phase I/IIa dose escalation study was designed to identify a genotypically optimized dose of Quinamed in heavily pre-treated patients with solid carcinomas. ChemGenex presented the results at the American Society of Clinical Oncology’s annual meeting last week in Chicago.